American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the stimulation of gamma delta T cells for treating solid tumors in epithelial cancers. U.S. Patent No: 9,914,938 dated March 13, 2018 further consolidates AGT’s intellectual property position surrounding its novel gene therapy platform. The patent describes AGT’s unique lentivirus vector approach to modify tumors for potent activation of naturally-occurring T cells in the immune system providing a highly-effective immune response and destruction of tumors.
{iframe}https://www.americangene.com/american-gene-technologies-gains-additional-immuno-oncology-patent/{/iframe}